Merck & Co backed a $14m series B for SAB Biotherapeutics, which is developing drugs for two forms of coronavirus including Covid-19.
US-based polyclonal antibody developer SAB Biotherapeutics today completed a $14m series B round featuring pharmaceutical firm Merck & Co.
The round was filled out by private equity firm South Dakota Equity Partners and multiple unnamed existing and private investors.
SAB Biotherapeutics is working on immunotherapies using a polyclonal antibody platform to address a range of diseases, including a phase 2-stage candidate, SAB-301, for Middle East respiratory syndrome (Mers) coronavirus – a form of contagious respiratory virus that can be fatal.
…
